Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Hybridoma Technology01:31

Hybridoma Technology

18.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer.

Molecular cancer therapeutics·2021
Same author

Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.

American journal of clinical oncology·2019
Same author

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.

Cancer immunology, immunotherapy : CII·2017
Same author

Discordant biological and toxicological species responses to TLR3 activation.

The American journal of pathology·2014
Same author

A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.

BMC cancer·2013
Same author

Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.

Cancer immunology, immunotherapy : CII·2011

Related Experiment Video

Updated: Apr 4, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Antibody-based immunotherapy of solid cancers: progress and possibilities.

Christopher F Nicodemus1

  • 1AIT Strategies, POB 429 Sunset Lane, Franconia, NH 03580, USA.

Immunotherapy
|August 29, 2015
PubMed
Summary

Engineered monoclonal antibodies offer new personalized cancer treatments by targeting both tumors and their microenvironment. This approach addresses challenges in solid tumors, unlike traditional methods.

Keywords:
IgEIgGPD-1T cellcheck pointipilimumabmacrophagemonocytemyeloidnivolumaboregovomabsecond signaltumor stroma

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Related Experiment Videos

Last Updated: Apr 4, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies are key in novel cancer therapeutics, with properties determined by antigen specificity and constant regions.
  • Advances in cancer biology and host-tumor interactions reveal new targets for antibody development.
  • Checkpoint inhibitors have validated immune modulation as a successful therapeutic strategy.

Purpose of the Study:

  • To review engineered monoclonal antibody products for personalized cancer treatment.
  • To highlight targeting strategies for both tumor cells and the tumor microenvironment.
  • To discuss the potential of antibodies in overcoming challenges posed by solid tumor stroma.

Main Methods:

  • Review of current literature on monoclonal antibody development in oncology.
  • Analysis of engineered antibody properties and their therapeutic implications.
  • Comparison of challenges in treating solid tumors versus hematologic malignancies.

Main Results:

  • Engineered monoclonal antibodies are emerging as central components of personalized cancer therapies.
  • Targeting tumor stroma, which contains immune-dampening elements, is crucial for solid tumor treatment.
  • Antibody engineering allows for tailored approaches to combat complex tumor biology.

Conclusions:

  • Engineered monoclonal antibodies represent a significant advancement in personalized cancer treatment paradigms.
  • The ability to target both tumor and stromal components offers a more comprehensive therapeutic strategy.
  • This approach holds promise for improving outcomes in solid cancer patients by modulating the tumor microenvironment.